Developing approaches, methods, and techniques to make biotherapeutics cheaper and safer.

Bioprocess Intensification

Bioprocess intensification refers to producing more biologics per unit of time, cost, footprint, and volume. Significant intensification can be achieved by both (i) small specific changes to the current development and manufacturing procedures and processes and (ii) more considerable disruptive changes that incorporate developing and implementing novel technologies.

“Single-Use Centrifugal Separator Enables Intensification of the Clarification Process in Biomanufacturing of Recombinant Proteins.” In review.

Biopharma 4.0

The biopharmaceutical industry is undergoing a digital transformation by incorporating tools and techniques that enable efficient data-driven decision-making across various biopharmaceutical discovery, development, and manufacturing activities. By adopting 4.0 technologies, biopharma companies can accelerate drug discovery and development, increase productivity and enhance regulatory compliance through effective process control, ultimately reducing costs and time associated with biologics development and manufacturing.

“Artificial neural network (ANN)‐based prediction of depth filter loading capacity for filter sizing.” Biotechnology Progress 32.6 (2016): 1436-1443.
“Application of Machine Learning in Ensuring Viral Safety of Biotherapeutics: Case Study Demonstrating Prediction and Optimization of Viral Clearance Performance of Anion Exchange Chromatography.” In review.

Continuous Bioprocessing

Switching from batch manufacturing to continuous enables a significant reduction in footprint, ultimately resulting in lower manufacturing costs. Continuous manufacturing processes can be scaled up quickly, based on the operation time, compared to batch processes that require volume-based scale-up. The smaller footprint, lower costs, and faster scale-up of continuous biomanufacturing enable biotherapeutics to be produced at a ‘pandemic pace’ and be accessible to low-income countries.

“Continuous processing for production of biopharmaceuticals.” Preparative Biochemistry and Biotechnology 45.8 (2015): 836-849.
“Integrated continuous processing of proteins expressed as inclusion bodies: GCSF as a case study.” Biotechnology progress 33.4 (2017): 998-1009

Publications and Patents

Sorry, no publications matched your criteria.